The biotechnology company has initially leased 5,000 sq ft on a ten-year lease following its announcement of a strategic collaboration with MEDINET, a Tokyo-listed immune-cell therapy company, to develop a novel treatment for various types of cancer.
TCB will license MEDINET’s innovative, proven cell therapy product to progress clinical development of the new treatment in the UK and Europe. TCB will establish a brand new clean room, lab and administration facility which will become a Scottish hub for immuno-cell therapy research to benefit cancer patients in the UK and Europe.
Dr Michael Leek, chief executive of TCB, said: “We are one important step forward to our goal of treating cancer patients with novel cell therapy and I couldn’t be more satisfied with our new location at Maxim Office Park. We have been working closely with the Maxim team to identify the best property for our needs and I’m confident the modern space will benefit our new facility and also provide us with room to grow as our company flourishes.”
TCB’s move to Maxim Office Park represents significant inward investment for Scotland’s cell therapy industry. The company has been awarded a significant amount of assistance from the Scottish Government in the form of Regional Selective Assistance (RSA) funding to enable
the creation of new highly skilled jobs, strategic input from Scottish Enterprise’s High Growth Start-Up Unit and funding of academic collaborations by Glasgow City Council.
Craig Ritchie, of Maxim Office Park, said: “It’s fantastic that Maxim is able to provide TCB with exactly the right facility for its scientific research needs. With flexible open plan units and a highly modern design, the space at Maxim lends itself particularly well to laboratories, as already evidenced by SEPA which took occupation of the 58,600 sq ft Maxim 6 building last year, allowing it to incorporate a first class laboratory facility alongside its office functions.